Read by QxMD icon Read

Metabolic sydrome

Ján Fedacko, Daniel Pella, Peter Jarcuska, Leonard Siegfried, Martin Janicko, Eduard Veselíny, Jozef Pella, Frantisek Sabol, Pavol Jarcuska, Mária Mareková, Andrea Madarasová Gecková, Peter Pazinka, Monika Jankajová, Ján Kmec, Marián Babcák, Peter Kalanin, Sylvia Drazilová, Ingrid Babinská, Beáta Cecetková
BACKGROUND: Obesity-induced metabolic syndrome is a multiple risk factor for cardiovascular (CV) risk factors and type 2 diabetes, and ethnic minorities seem to have unfavourable medical risk factors in general more frequently than majority populations. OBJECTIVE: The aim of this study was to evaluate the prevalence of cardiovascular risk factors in relation to metabolic syndrome in the Roma population compared with the non-Roma population residing in the eastern part of Slovakia...
March 2014: Central European Journal of Public Health
Andrzej Januszewicz, Aleksander Prejbisz, Elżbieta Florczak
No abstract text is available yet for this article.
2013: Pneumonologia i Alergologia Polska
Aysem Kaya, Isil Uzunhasan, Murat Baskurt, Alev Ozkan, Esra Ataoglu, Baris Okcun, Zerrin Yigit
BACKGROUND: Metabolic syndrome is associated with cardiovascular disease and oxidative stress. The aim of this study was to investigate the differences of novel oxidative stress parameters and lipid profiles in men and women with metabolic syndrome. METHODS: The study population included 88 patients with metabolic syndrome, consisting of 48 postmenauposal women (group I) and 40 men (group II). Premenauposal women were excluded. Plasma levels of total antioxidant status (TAS) and total oxidative status (TOS) were determined by using the Erel automated measurement method, and oxidative stress index (OSI) was calculated...
February 2010: Metabolic Syndrome and related Disorders
David K Murdock, Darlaen Jansen, Ryan M Juza, Mary Kersten, Karen Olson, Bryan Hendricks
Statins frequently do not control all of the lipid abnormalities found in patients with the metabolic sydrome. Pioglitizone (PIO), an insulin sensitizing agent, has been shown to have favorable lipid effects in diabetic patients. Little information is available regarding the effect of combined statin and PIO therapy in non-diabetic patients with the metabolic syndrome. We report our experience of adding PIO to statin therapy in non-diabetic patients with the metabolic syndrome. Pioglitazone was administered to 24 non-diabetic patients in our lipid clinic who were already on a statin yet continued to have significant lipid abnormalities...
July 2006: WMJ: Official Publication of the State Medical Society of Wisconsin
I N Medvedev, N I Gromnatsiĭ
The research was undertaken with the purpose to assess the efficiency of nebivolol for correction of thrombocyte aggregation capability in patients having arterial hypertension (AH) with metabolic syndrome (MS). 21 patients were administered nebivolol in a dose of 5 mg per day for a month. The dynamic changes in the following parameters were evaluated: anthropometric measurements, blood lipid spectrum, lipid peroxidation in serum and thrombocytes, antioxidative protectability of the liquid part of blood and platelets, thrombocyte aggregation activity...
2005: Klinicheskaia Meditsina
Christian E Berger, Andreas Kröner, Helmar Stiegler, Michael Erdel, Oskar A Haas, Alfred Engel
Parameters of hypofibrinolysis and thrombophilia were assessed in 20 consecutive patients with bone marrow edema sydrome of the hip who lacked typical risk factors for osteonecrosis. Twenty healthy subjects, matched for age and gender, served as the control subjects. In patients with bone marrow edema syndrome, elevated levels of lipoprotein(a) and plasminogen activator inhibitor were found in nine (45%) and two patients (10%), respectively. Elevation of lipoprotein(a) was present in two patients in the control group; however, plasminogen activator inhibitor levels were normal in this group...
April 2002: Clinical Orthopaedics and related Research
C Almog, E Tal
No abstract text is available yet for this article.
1968: Confinia Neurologica
G R Heninger, P S Mueller, L S Davis
Patients with severe depression have been observed previously to have a reduced rate of glucose utilization accompanied by elevated serum insulin levels during the intravenous glucose tolerance test (GTT) and a reduced metabolic responsiveness to exogenous insulin during the insulin tolerance test (ITT). These abnormalities were less obvious in patients with neurotic depression as compared to patients with severe endogenous or "psychotic" depression. To evaluate more fully the relationships of depressive symptomatology to these metabolic abnormalities, patients were rated by nursing staff on a short clinical rating scale (SCRS) and by a psychiatrist on the Brief Psychiatric Rating Scale (BPRS) at the time the metabolic measurements were made...
December 1975: Journal of Nervous and Mental Disease
M Dragomirescu
No abstract text is available yet for this article.
January 1978: Revista de Medicină Internă, Neurologe, Psihiatrie, Neurochirurgie, Dermato-venerologie. Medicină Internă
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"